Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Biochrom Introduces EZ Nin Reagent for Improved Amino Acid Analysis

Published: Tuesday, February 25, 2014
Last Updated: Monday, February 24, 2014
Bookmark and Share
Ready to use ninhydrin formulation for ion exchange chromatography systems.

Biochrom Ltd has announced the commercial launch of its EZ Nin Reagent™, a ready-to-use ninhydrin formulation for use in ion exchange chromatography systems with post-column derivatisation for improved amino acid analysis.

The newly launched and patent protected EZ Nin Reagent has been developed to save laboratory time and waste; it requires no mixing or nitrogen and does not degrade with time or exposure to oxygen, providing reliable analysis over time without loss of sensitivity.

Challenges encountered with standard ninhydrin include the long preparation process, instability of the reagent, degradation and waste, and batch-to-batch variability.

Each batch of EZ Nin Reagent is identically prepared, enabling the reagent to be topped up on the instrument, eliminating waste or the risk of running out during a series of analyses. EZ Nin Reagent is methanol and hydrindantin free.

Tristana von Will, Product Marketing Manager at Biochrom, commented: “Biochrom’s formulation combines ease of use with unprecedented chemical stability, providing laboratories with the confidence they require when evaluating concentrations of amino acids for diagnosis and monitoring of inborn errors of metabolism (IEMs).”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Biochrom, Gilson Sign ELISA Distribution Agreement
Companies to co-market and distribute products for automation of ELISAs and other absorbance assays in Europe.
Tuesday, June 10, 2014
Scientific News
New Cancer Drug Target in Dual-Function Protein
Scientists at The Scripps Research Institute (TSRI) have identified a protein that launches cancer growth and appears to contribute to higher mortality in breast cancer patients.
Penn State, TB Alliance, and GSK Partner To Discover New Treatments For TB
A new collaboration between TB Alliance, GSK, and scientists in the Eberly College of Science seeks to find new small molecules that can be used to create antibiotics in the fight against tuberculosis (TB).
Molecular Map Provides Clues To Zinc-Related Diseases
Mapping the molecular structure where medicine goes to work is a crucial step toward drug discovery against deadly diseases.
Platelets are the Pathfinders for Leukocyte Extravasation During Inflammation
Findings from the study could help in the prevention and treatment of inflammatory pathologies.
Genetic Research Can Significantly Improve Drug Development
With drug development costs topping $1.2bn (£850 million) to get a single treatment to the point it can be sold and used in the clinic, could genetic analysis save hundreds of millions of dollars?
New Method Opens Door to Development of Many New Medicines
Findings from TSRI reveal human proteins are better drug targets than previously thought.
Diagnosing Systemic Infections Quickly, Reliably
Team develop rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Blood Test That Detects Early Alzheimer’s Disease
A research team, led by Dr. Robert Nagele from Rowan University School of Osteopathic Medicine and Durin Technologies, Inc., has announced the development of a blood test that leverages the body’s immune response system to detect an early stage of Alzheimer’s disease – referred to as the mild cognitive impairment (MCI) stage – with unparalleled accuracy.
A New Approach to Chemical Synthesis
Communesins, originally found in fungus, could hold potential as cancer drugs.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!